• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Intergalactic Therapeutics announces closing


The gene therapy company announces its closure less than 2 years after the company launch in 2021.

a closed sign in the window of a business (Image Credit: AdobeStock/NYgraphic)

(Image Credit: AdobeStock/NYgraphic)

Intergalactic Therapeutics, a company specializing in developing non-viral gene therapies based in Cambridge, MA, announced its closing this week. This comes less than 2 years after the company launch in 2021.

Joseph W. Graskemper, in charge of external manufacturing and supply chain operations, posted on Linked-in, “The current economic environment has led to challenging times for companies to raise capital. As a result, many companies are reducing staff or halting operations completely. Unfortunately, Intergalactic Therapeutics was not immune to these challenges and all employees have been laid off, myself included.”

In late June 2023, the company announced positive results achieved with its non-viral gene therapy platform in ABCA4 retinopathies in non-human primates

At that time, the company announced the following top line results: “Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human primate retinas over 6 months after a single administration. Findings build on 12-month durability data achieved in adult porcine retinas also after a single administration. The data support plan to advance IG-002 into Phase 1 trials in 2024.”

Related Videos
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Jay Barth, MD
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Stargardt research: Therapy on the horizon for inherited retinal disease
© 2024 MJH Life Sciences

All rights reserved.